ANGO — Angiodynamics Income Statement
0.000.00%
Last trade - 00:00- $255.15m
- $176.70m
- $338.75m
- 68
- 54
- 46
- 57
Annual income statement for Angiodynamics, fiscal year end - May 31st, USD millions except per share, conversion factor applied.
2019 May 31st | 2020 May 31st | 2021 May 31st | 2022 May 31st | 2023 May 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 271 | 264 | 291 | 316 | 339 |
| Cost of Revenue | |||||
| Gross Profit | 156 | 150 | 157 | 166 | 174 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 280 | 431 | 326 | 345 | 390 |
| Operating Profit | -9.4 | -167 | -35.3 | -28.5 | -51.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -14.7 | -168 | -36.1 | -29.9 | -54.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -11.1 | -167 | -31.5 | -26.5 | -52.4 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 61.3 | -167 | -31.5 | -26.5 | -52.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 61.3 | -167 | -31.5 | -26.5 | -52.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.035 | -1.58 | -0.48 | -0.53 | -0.831 |